135 related articles for article (PubMed ID: 22339831)
1. [Clinical analysis of bortezomib combined with chemotherapy for one case of refractory acute lymphocytic leukemia].
Xu JJ; Hu XH; Shen YY
Zhonghua Xue Ye Xue Za Zhi; 2011 Oct; 32(10):697-8. PubMed ID: 22339831
[No Abstract] [Full Text] [Related]
2. Side effects and good effects from new chemotherapeutic agents. Case 3. Bortezomib in primary refractory plasmacytoma.
Chim CS; Ooi GC; Loong F; Au AW; Lie AK
J Clin Oncol; 2005 Apr; 23(10):2426-8. PubMed ID: 15800336
[No Abstract] [Full Text] [Related]
3. Recent advancements of bortezomib in acute lymphocytic leukemia treatment.
Du XL; Chen Q
Acta Haematol; 2013; 129(4):207-14. PubMed ID: 23295437
[TBL] [Abstract][Full Text] [Related]
4. Bortezomib therapy following first relapse.
Orlowski RZ;
Oncology (Williston Park); 2005 Jan; 19(1):23-6. PubMed ID: 15743149
[No Abstract] [Full Text] [Related]
5. Bortezomib data show improved survival in patients with relapsed multiple myeloma.
Oncology (Williston Park); 2004 Aug; 18(9):1199, 1201. PubMed ID: 15471202
[No Abstract] [Full Text] [Related]
6. Morphoproteomics and bortezomib/dexamethasone-induced response in relapsed acute lymphoblastic leukemia.
Brown RE; Bostrom B; Zhang PL
Ann Clin Lab Sci; 2004; 34(2):203-5. PubMed ID: 15228234
[TBL] [Abstract][Full Text] [Related]
7. Complete remission and successful stem cell mobilization after treatment of refractory plasma cell leukemia with bortezomib.
Grassinger J; Südhoff T; Andreesen R; Hennemann B
Ann Hematol; 2006 Feb; 85(2):132-3. PubMed ID: 16311736
[No Abstract] [Full Text] [Related]
8. Phase I study of bortezomib in refractory or relapsed acute leukemias.
Cortes J; Thomas D; Koller C; Giles F; Estey E; Faderl S; Garcia-Manero G; McConkey D; Ruiz SL; Guerciolini R; Wright J; Kantarjian H
Clin Cancer Res; 2004 May; 10(10):3371-6. PubMed ID: 15161691
[TBL] [Abstract][Full Text] [Related]
9. Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing program.
Houghton PJ; Morton CL; Kolb EA; Lock R; Carol H; Reynolds CP; Keshelava N; Maris JM; Keir ST; Wu J; Smith MA
Pediatr Blood Cancer; 2008 Jan; 50(1):37-45. PubMed ID: 17420992
[TBL] [Abstract][Full Text] [Related]
10. Incorporating bortezomib into the treatment of lung cancer.
Davies AM; Lara PN; Mack PC; Gandara DR
Clin Cancer Res; 2007 Aug; 13(15 Pt 2):s4647-51. PubMed ID: 17671158
[TBL] [Abstract][Full Text] [Related]
11. A modified regimen of pegylated liposomal doxorubicin, bortezomib, and dexamethasone is effective and well tolerated in the treatment of relapsed or refractory multiple myeloma.
Waterman GN; Yellin O; Swift RA; Mapes R; Eades B; Ackerman E; Berenson JR
Ann Hematol; 2011 Feb; 90(2):193-200. PubMed ID: 20809423
[TBL] [Abstract][Full Text] [Related]
12. Impact of prior therapies on the relative efficacy of bortezomib compared with dexamethasone in patients with relapsed/refractory multiple myeloma.
Vogl DT; Stadtmauer EA; Richardson PG; Sonneveld P; Schuster MW; Irwin D; Facon T; Harousseau JL; Boral A; Neuwirth R; Anderson KC
Br J Haematol; 2009 Nov; 147(4):531-4. PubMed ID: 19725827
[TBL] [Abstract][Full Text] [Related]
13. [The clinical study on treatment with bortezomib for multiple myeloma].
Chen C; Zhao CL; Hou M
Zhonghua Xue Ye Xue Za Zhi; 2011 Apr; 32(4):265-7. PubMed ID: 21569711
[No Abstract] [Full Text] [Related]
14. Updated survival analyses after prolonged follow-up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma.
Jagannath S; Barlogie B; Berenson JR; Siegel DS; Irwin D; Richardson PG; Niesvizky R; Alexanian R; Limentani SA; Alsina M; Esseltine DL; Anderson KC
Br J Haematol; 2008 Nov; 143(4):537-40. PubMed ID: 18783399
[TBL] [Abstract][Full Text] [Related]
15. Sequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed multiple myeloma: results of a phase II trial.
Kim HJ; Yoon SS; Lee DS; Sohn SK; Eom HS; Lee JL; Chung JS; Kim K; Suh C; Won JH; Kim JS; Park JS; Kang HJ; Seong CM; Kim CS; Lee SJ; Lee JH
Ann Hematol; 2012 Feb; 91(2):249-56. PubMed ID: 21789621
[TBL] [Abstract][Full Text] [Related]
16. Response to bortezomib of a patient with scleromyxedema refractory to other therapies.
Migkou M; Gkotzamanidou M; Terpos E; Dimopoulos MA; Kastritis E
Leuk Res; 2011 Nov; 35(11):e209-11. PubMed ID: 21831425
[No Abstract] [Full Text] [Related]
17. Phase II study of single-agent bortezomib for the treatment of patients with fludarabine-refractory B-cell chronic lymphocytic leukemia.
Faderl S; Rai K; Gribben J; Byrd JC; Flinn IW; O'Brien S; Sheng S; Esseltine DL; Keating MJ
Cancer; 2006 Sep; 107(5):916-24. PubMed ID: 16832816
[TBL] [Abstract][Full Text] [Related]
18. Differential ex vivo activity of bortezomib in newly diagnosed paediatric acute lymphoblastic and myeloblastic leukaemia.
Szczepanek J; Pogorzala M; Konatkowska B; Juraszewska E; Badowska W; Olejnik I; Kuzmicz M; Stanczak E; Malinowska I; Stefaniak J; Sobol G; Szczepanski T; Czyzewski K; Wysocki M; Styczynski J
Anticancer Res; 2010 Jun; 30(6):2119-24. PubMed ID: 20651360
[TBL] [Abstract][Full Text] [Related]
19. [Bortezomib].
Simons S; Scheulen ME; Jaehde U
Dtsch Med Wochenschr; 2006 Feb; 131(5):214-8. PubMed ID: 16440269
[No Abstract] [Full Text] [Related]
20. Treatment of human chronic lymphocytic leukemia cells with the proteasome inhibitor bortezomib promotes apoptosis.
Kelley TW; Alkan S; Srkalovic G; Hsi ED
Leuk Res; 2004 Aug; 28(8):845-50. PubMed ID: 15203282
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
